Nascent Biotech Inc.
NBIO evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Market Cap:
- $86K
- Lead Asset:
- pritumumab (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$86K
Cash Runway
—
Lead Asset
pritumumab (Phase 1)
Next Catalyst
—
Tracking 1 pipeline candidate for Nascent Biotech Inc..
Similar companies
Run Nascent Biotech Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nascent Biotech Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is Nascent Biotech Inc.'s lead drug candidate?
Nascent Biotech Inc.'s most advanced tracked candidate is pritumumab (Phase 1) for Brain cancer (including glioblastoma and malignant astrocytoma), pancreatic cancer, lung cancer, breast cancer, and colon cancer.
Who is the CEO of Nascent Biotech Inc.?
Mr. Sean Carrick is the chief executive officer of Nascent Biotech Inc. (NBIO).
Where is Nascent Biotech Inc. headquartered?
Nascent Biotech Inc. (NBIO) is headquartered in North Palm Beach, FL, United States.
What therapeutic areas does Nascent Biotech Inc. focus on?
Nascent Biotech Inc. develops therapies across Oncology, Neurology, Cardiovascular, Infectious Disease, Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.